Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Dementia Consortium

- PMLiVE

Merck to acquire Imago BioSciences in deal worth $1.35bn

The agreement includes lead candidate, bomedemstat, for myeloproliferative neoplasms

- PMLiVE

Takeda’s Exkivity receives NICE recommendation for rare form of lung cancer

Patients with EGFR Exon20ins+ NSCLC make up approximately 2% of NSCLC cases

- PMLiVE

MSD’s Vaxneuvance approved by MHRA for prevention of pneumococcal diseases in children

The decision marks the first new vaccine approved by MHRA in a decade for this indication

- PMLiVE

Eli Lilly set to launch Tempo Personalized Diabetes Management Platform

Users can use the app to log insulin doses, set reminders and access education resources

- PMLiVE

Boehringer and Lilly’s Jardiance shows promise in phase 3 chronic kidney disease trial

Jardiance reduced disease progression and cardiovascular death by 28%

- PMLiVE

Eli Lilly and Purdue sign $92.5m deal for pharma manufacturing scholarships

Participating students with be able to compete for a role at the company following graduation

- PMLiVE

Takeda’s dengue vaccine candidate recommended for approval by CHMP

Dengue disease causes around 390 million infections and 500,000 hospitalisations each year

- PMLiVE

New study finds signs of dementia could be detected nine years before diagnosis

Impairment was observed in several areas across a range of dementia-related diseases

- PMLiVE

New study links omega-3 intake in midlife to reduced dementia risk

Over 2,000 people who did not have dementia or stroke took part in the study

- PMLiVE

Eli Lilly granted fast track designation by FDA for obesity treatment

The company plans to initiate a rolling submission of a new drug application for tirzepatide this year

- PMLiVE

New study finds brains of ‘superagers’ contain larger neurones in memory region

Superagers had 'significantly larger' brain cells in a region of the brain that is critical for memory

- PMLiVE

Biogen and Eisai’s lecanemab shows promise in confirmatory Alzheimer’s study

Results from the phase 3 trial showed reduction in clinical decline

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links